Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma

Completed · Phase 1

Conditions studied: Open-angle Glaucoma

In brief

This is a multi center, open-label, single dose, safety study. Approximately 9 to 15 participants with open-angle glaucoma are assigned into 3 sequential dose-levels and will receive ANX007 administered as single, IVT injections.

Key facts

Study ID

NCT03488550

Run by

Annexon, Inc.

People needed

9

Starts

2018-03-23

Expected to finish

2018-08-03

Last updated by the study team

2020-08-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female age 18 years and older
• Diagnosis of primary open-angle glaucoma
• Intraocular pressure <21 mm Hg on a stable IOP treatment regimen
• Reliable visual field testing

You may not qualify if…

• BCVA worse than 20/80 in either eye
• Extensive glaucomatous visual-field damage
• History of intraocular inflammatory or infectious eye disease in study eye
• Ocular trauma in study eye within the preceding 6 months
• History of uncomplicated cataract surgery less than 6 mos prior
• Any abnormality preventing reliable Tonopen tonometry in study eye
• Active malignancy within past 5 yrs
• Previous tx with another humanized monoclonal antibody
• History of any autoimmune or neurologic disease
• Concurrent use of glucocorticoid medications
• Receiving monoamine oxidase inhibitor therapy

Where it is running

• Eye Research Foundation — Newport Beach, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.